Affiliation: Massachusetts General Hospital
- Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysisEnrico Tedeschini
Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Eur Neuropsychopharmacol 20:562-7. 2010..An increased likelihood of receiving placebo did not inflate discontinuation rates which did not influence the degree of antidepressant-placebo "separation"...
- Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approachEnrico Tedeschini
Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
J Clin Psychiatry 72:98-113. 2011..In order to accomplish this, we examined the relationship between a "positive" or "negative" finding early on (weeks 1-4), and outcome at end point...
- Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressantsMarlene P Freeman
Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
J Clin Psychiatry 71:682-8. 2010....
- Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trialsNadia Iovieno
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 72:1144-51. 2011....
- Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trialsNadia Iovieno
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Int J Neuropsychopharmacol 15:289-96. 2012....
- Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trialsNadia Iovieno
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Int Clin Psychopharmacol 26:69-74. 2011..placebo) in this population as they are in the general MDD population. Higher general response rates observed in the co-morbid MDD population are intriguing, and require replication...
- Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysisPaola Pedrelli
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 31:582-6. 2011..Future studies examining the effectiveness of antidepressants while controlling for several variables such as psychosocial treatment and assessing the specific classes of antidepressants are needed...
- Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitorsGeorge I Papakostas
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Eur Neuropsychopharmacol 22:347-55. 2012..These findings are preliminary, of yet undetermined clinical relevance, and warrant replication and further exploration...
- Adjunctive pregabalin in partial responders with major depressive disorder and residual anxietyMario Vitali
Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy
J Clin Psychopharmacol 33:95-8. 2013..Anxiety symptoms in depression result often in treatment resistance, residual symptoms, and persistent functional impairment...